September 9, 2024 11:31 AM EDT
R&D

#ES­MO24 roundup: New da­ta on Am­gen’s PRMT5 in­hibitor seem lack­lus­ter, and Jazz’s HER2 an­ti­body

Lei Lei Wu

News Reporter

On Sun­day evening, ab­stracts from the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy were re­leased. While some of on­col­o­gy’s most ex­cit­ing re­cent da­ta were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times